Bristol Gate Capital Partners Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$23.4M |
| 2 |
Roper Technologies
ROP
|
+$23.1M |
| 3 |
Kroger
KR
|
+$22.4M |
| 4 |
Tyson Foods
TSN
|
+$21.5M |
| 5 |
CVS Health
CVS
|
+$4.48M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Union Pacific
UNP
|
+$20.5M |
| 2 |
Moody's
MCO
|
+$19.6M |
| 3 |
International Flavors & Fragrances
IFF
|
+$19.3M |
| 4 |
Trane Technologies
TT
|
+$19M |
| 5 |
Hormel Foods
HRL
|
+$2.11M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 23.36% |
| 2 | Consumer Discretionary | 22.37% |
| 3 | Consumer Staples | 13.98% |
| 4 | Industrials | 13.69% |
| 5 | Financials | 13.23% |
Similar funds
Bristol Gate Capital Partners's Q4 2015 Portfolio in Review
As of Q4 2015, Bristol Gate Capital Partners held 26 positions worth $515M, up 17% from $439M the previous quarter. Its ten largest holdings account for 47% of the portfolio.
Bristol Gate Capital Partners deployed $42.5M of net new capital in Q4 2015, opening 4 new positions and adding to 16 existing holdings. Its largest new stake was Amgen: 149,087 shares worth $24.2M.
By sector, the portfolio is most concentrated in Healthcare at 23% of assets, up from 18% a quarter earlier, followed by Consumer Discretionary and Consumer Staples.
On the sell side, the largest reduction was Hormel Foods, an estimated $2.11M trimmed.
- Bristol Gate Capital Partners's largest Q4 2015 buy was Amgen: 149,087 shares worth $24.2M.
- Bristol Gate Capital Partners added most to CVS Health in Q4 2015, an estimated $4.48M increase.
- Bristol Gate Capital Partners's biggest Q4 2015 reduction was Hormel Foods, cutting an estimated $2.11M.
- Bristol Gate Capital Partners fully exited Union Pacific in Q4 2015, selling an estimated $20.5M.
- Bristol Gate Capital Partners's ten largest holdings make up 47% of its $515M portfolio in Q4 2015.
- Bristol Gate Capital Partners opened 4 new positions and closed 4 in Q4 2015.
- Bristol Gate Capital Partners's portfolio value rose 17% quarter-over-quarter to $515M.
Based on Bristol Gate Capital Partners's 13F filing for Q4 2015, filed 8 Feb 2016.